Table 3 Changes in cardiovascular medication
From: Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes
|  | Baseline (n = 97) | 3 months (n = 94) | 2 years (n = 77) | p-value (baseline - 3 months) | p-value (baseline - 2 years) |
|---|---|---|---|---|---|
Glucose lowering treatment (%) | Â | Â | Â | Â | Â |
Metformin | 62.9 | 75.5 | 67.1 | 0.001 | 0.655 |
Acarbose | 3.1 | 2.1 | 1.2 | 0.320 | 0.317 |
Sulfonylureas | 24.7 | 29.8 | 19.5 | 0.158 | 0.285 |
Glitazones | 11.3 | 25.5 | 19.5 | <0.001 | 0.058 |
DPP-IV Inhibitors | 9.3 | 19.1 | 26.8 | 0.002 | 0.001 |
Insulin | 26.8 | 32.3 | 29.3 | 0.027 | 0.105 |
Other OADs | 3.1 | 3.3 | 2.4 | 1.000 | 0.564 |
Lipid lowering treatment (%) | Â | Â | Â | Â | Â |
Statins | 35.1 | 73.4 | 68.3 | <0.001 | <0.001 |
Ezetimibe | 4.1 | 4.3 | 1.2 | 1.000 | 0.157 |
Fibrates | 6.2 | 7.5 | 4.8 | 0.564 | 1.000 |
Antihypertensive treatment (%) | Â | Â | Â | Â | Â |
ACE-Inhibitors | 46.4 | 61.7 | 46.3 | <0.001 | 1.000 |
Ca-channel blockers | 21.6 | 47.9 | 46.3 | <0.001 | <0.001 |
Beta-blockers | 35.1 | 40.4 | 42.7 | 0.102 | 0.109 |
AT2-blockers | 21.6 | 28.7 | 30.0 | 0.033 | 0.132 |
Other Antihypertensives | 37.1 | 46.8 | 42.5 | 0.020 | 0.516 |